Vor Biopharma (NASDAQ:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 70,763 Shares

Key Points

• Major shareholder Reprogrammed Interchange LLC sold a total of 70,763 shares of Vor Biopharma, representing a 4.43% decrease in their ownership stake, with the latest sale valued at approximately $2.62 million.
• Vor Biopharma's stock price has recently declined by 1.2%, trading at $33.40, after experiencing a drop in market interest and volatility reflected in a beta of 2.07.
• The company reported ($43.60) EPS for the last quarter, falling short of estimates and reflecting significant financial challenges, with a current market capitalization of $228.79 million.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 70,763 shares of the firm's stock in a transaction on Monday, October 6th. The shares were sold at an average price of $37.01, for a total value of $2,618,938.63. Following the sale, the insider directly owned 1,526,545 shares in the company, valued at approximately $56,497,430.45. This trade represents a 4.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Tuesday, October 7th, Reprogrammed Interchange Llc sold 27,624 shares of Vor Biopharma stock. The stock was sold at an average price of $33.84, for a total value of $934,796.16.
• On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The stock was sold at an average price of $37.83, for a total value of $298,894.83.
• On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The stock was sold at an average price of $39.83, for a total value of $1,292,523.33.
• On Wednesday, October 1st, Reprogrammed Interchange Llc sold 1,400 shares of Vor Biopharma stock. The stock was sold at an average price of $39.19, for a total value of $54,866.00.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The stock was sold at an average price of $1.54, for a total value of $688,808.12.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The shares were sold at an average price of $30.80, for a total value of $688,780.40.
• On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The shares were sold at an average price of $32.80, for a total value of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The shares were sold at an average price of $35.00, for a total value of $525,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 14,240 shares of Vor Biopharma stock. The shares were sold at an average price of $36.60, for a total value of $521,184.00.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 23,221 shares of Vor Biopharma stock. The shares were sold at an average price of $39.80, for a total value of $924,195.80.

Vor Biopharma Stock Down 1.2%

Shares of NASDAQ:VOR traded down $0.40 during midday trading on Wednesday, reaching $33.40. The company's stock had a trading volume of 436,485 shares, compared to its average volume of 391,343. The firm has a market capitalization of $228.79 million, a price-to-earnings ratio of -0.12 and a beta of 2.07. The stock has a 50 day moving average of $38.36. Vor Biopharma Inc. has a fifty-two week low of $2.62 and a fifty-two week high of $65.80.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($11.40) by ($32.20).

Institutional Investors Weigh In On Vor Biopharma

Large investors have recently added to or reduced their stakes in the stock. OMERS ADMINISTRATION Corp bought a new stake in shares of Vor Biopharma during the 1st quarter valued at $100,000. Goldman Sachs Group Inc. grew its position in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after acquiring an additional 58,247 shares during the period. Money Concepts Capital Corp grew its position in shares of Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after acquiring an additional 26,535 shares during the period. Jane Street Group LLC bought a new stake in shares of Vor Biopharma during the 1st quarter valued at $140,000. Finally, XTX Topco Ltd bought a new stake in shares of Vor Biopharma during the 2nd quarter valued at $66,000. Institutional investors own 97.29% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Wall Street Zen lowered Vor Biopharma to a "strong sell" rating in a research report on Saturday, June 28th. Stifel Nicolaus raised Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 price objective for the company in a report on Wednesday, September 24th. HC Wainwright reissued a "buy" rating and set a $60.00 price objective on shares of Vor Biopharma in a report on Thursday, August 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Vor Biopharma in a report on Wednesday. Finally, Wedbush reaffirmed an "outperform" rating on shares of Vor Biopharma in a report on Thursday, June 26th. Five investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Vor Biopharma currently has an average rating of "Hold" and a consensus price target of $113.83.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.